EHA 2015: Updated results from SORAML – the first randomised trial of a tyrosine kinase inhibitor in younger patients with newly diagnosed AML

The randomised, controlled phase 2 SORAML trial showed that the addition of the tyrosine kinase inhibitor, sorafenib, to chemotherapy improved event-free survival and relapse-free survival in younger patients with acute myeloid leukaemia (AML).

Presented by Gerhard Ehninger, MD, Technical University Dresden, Dresden, Germany, at the 20th Congress of the European Hematology Association (EHA)

European Medical Journal

Website: http://emjreviews.com/
Twitter: https://twitter.com/EMJReviews
Facebook: https://www.facebook.com/emjreviews